HOME > MARKETS > COMPANY NEWS
  COMPANY NEWS
COMPANY
Natco Pharma supports Columbia University's clinical trial of chloroquine phosphate
May-23-2020
Natco Pharma has reiterated its commitment in supporting a clinical trial to prevent symptomatic SARS-CoV-2 infections by donating Chloroquine Phosphate (CQ) Tablets through its marketing partner in the United States, Rising Pharmaceuticals, to a study conducted by Columbia University, New York.

After Natco's recent donation to a global clinical trial conducted by the CROWN (COVID-19 Research Outcomes Worldwide Network) Collaborative at the Washington University School of Medicine in St. Louis it has now committed to support the Phase 2 of a clinical trial at Columbia University. The trial aims to determine the effectiveness of CQ in preventing COVID-19 infection in healthcare workers with moderate to high risk of exposure to the virus.

Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets.
  RELATED NEWS >>